Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus Q PAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus Q PAM.
ALFUZOSIN HYDROCHLORIDE vs Q-PAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker